AuntMinnie

MARCH 15, 2024

A 2018 study from the U.S. An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Americans today can expect to live long lives.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Disease Diagnostic Imaging 105

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,

Radiopharmaceuticals 105

Radiopharmaceuticals Radiosensitivity Medical Diagnostic 105

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 Blue Earth Diagnostics received U.S.

Clinic 98

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 98

AuntMinnie

OCTOBER 25, 2024

An assistant professor of radiology and radiological science, Francis Deng, MD, is the Johns Hopkins radiology department's co-director of medical student diagnostic radiology electives. His area of expertise is neuroradiology, with a special emphasis on diagnostic imaging of the head, neck, brain, and spine. Kori Stewart, PhD.

Nuclear Medicine 143

Nuclear Medicine Education Radiology Technologist Radiation Science 143

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Blue Earth Diagnostics received U.S.

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97